BCRX Financial Facts
Research and development: 14.11MNet loss: -11.53M
See Full Income Statement
Total stockholders' equity: 3.99M
Furniture and equipment, net: 10.1M
See Full Balance Sheet
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings
|
Expand Research on BCRX
| Next EPS Date | 5/2/24 | EPS Growth Rate | +25.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +3.6% | Revenue Growth Rate | +26.2% |
| Average % Move 1-Wk after EPS | +2.7% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
2/23/22  |
Q4 | -$0.40 | N/A | N/A | $47.2M | $4M | N/A |  | | Details | |
| 2/21/23 | Q422 | -$0.38 | -$0.17 | -$0.21 | $79.5M | $75.57M | N/A | | | Details | |
| 8/4/11 |
 |
Q211 | -$0.36 | -$0.25 | -$0.11 | $3.7M | $8.04M | N/A | | | Details |
| 11/1/22 | Q322 | -$0.33 | -$0.29 | -$0.04 | $40.99M | $74.62M | N/A | | | Details | |
| 11/2/11 |
|
Q311 | -$0.32 | -$0.26 | -$0.06 | $5.25M | $6.84M | N/A | | | Details |
| 8/4/22 | Q222 | -$0.32 | -$0.34 | +$0.02 | $65.2M | $63.33M | N/A | | | Details | |
| 5/5/16 |
Q116 | -$0.31 | -$0.23 | -$0.08 | $4.82M | $5.42M | N/A | | | Details | |
| 2/16/12 |
|
Q411 | -$0.29 | -$0.29 | $0.00 | $5.2M | $7.34M | = | | | Details |
